SEC Contract Filing

Filing Date: 2015-05-07

Document Content:
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>ex102.htm
<DESCRIPTION>EXHIBIT 10.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
 <!-- Document created using Wdesk 1 -->
 <!-- Copyright 2015 Workiva -->
 <title>EX 10.2</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="s615828DC8A45B69DB1A22A906954C5F9"></a><div><div style="line-height:120%;text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">Exhibit 10.2</font></div><div style="line-height:120%;text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">EXECUTION VERSION</font></div><div style="line-height:120%;text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;text-decoration:underline;">STRICTLY CONFIDENTIAL</font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;text-decoration:underline;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">FIRST AMENDMENT TO </font></div><div style="line-height:120%;padding-bottom:24px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">TERMINATION AND ASSET TRANSFER AGREEMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;FIRST AMENDMENT TO THE TERMINATION AND ASSET TRANSFER AGREEMENT</font><font style="font-family:inherit;font-size:12pt;">&#32;(this&#160;&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Amendment</font><font style="font-family:inherit;font-size:12pt;">&#8221;) is entered into as of January 19, 2015 (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Amendment Date</font><font style="font-family:inherit;font-size:12pt;">&#8221;) by and between Novartis Pharma AG, a Swiss corporation (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Novartis</font><font style="font-family:inherit;font-size:12pt;">&#8221;); Novartis International Pharmaceutical Ltd., a corporation organized and existing under the laws of Bermuda, for purposes of </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Article II</font><font style="font-family:inherit;font-size:12pt;">, </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 4.1</font><font style="font-family:inherit;font-size:12pt;">, </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Section 5.1(d)</font><font style="font-family:inherit;font-size:12pt;">&#32;and </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Article X</font><font style="font-family:inherit;font-size:12pt;">&#32;only of the Agreement (as defined below) (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NIP</font><font style="font-family:inherit;font-size:12pt;">&#8221;); and Array BioPharma Inc., a Delaware corporation (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Array</font><font style="font-family:inherit;font-size:12pt;">&#8221;). </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">WHEREAS</font><font style="font-family:inherit;font-size:12pt;">, Array, Novartis and NIP are parties to that certain Termination and Asset Transfer Agreement, dated as of November 26, 2014 (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Original Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221; and as amended by this Amendment, the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221;); and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">WHEREAS</font><font style="font-family:inherit;font-size:12pt;">, Array, Novartis and NIP desire to amend the Original Agreement as set forth herein. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOW, THEREFORE</font><font style="font-family:inherit;font-size:12pt;">, in consideration of the foregoing premises and the mutual covenants and agreements hereinafter set forth, the parties hereto, intending to be legally bound, hereby agree as follows: </font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:0px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:12pt;color:#010000;padding-right:48px;">1.</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Defined Terms</font><font style="font-family:inherit;font-size:12pt;">. All capitalized terms used but not defined herein shall have the meanings specified in the Original Agreement. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;color:#010000;">2.</font><font style="font-family:inherit;font-size:10